Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes

Area of Science:

• Biomedical Science
• Cardiovascular Research
• Drug Discovery

Background:

• Cardiotoxicity is a significant challenge in developing new drugs.
• Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) offer a promising model for assessing drug-induced heart damage.
• The predictive consistency between human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) requires further investigation.

Purpose of the Study:

• To evaluate the cardiotoxicity prediction consistency between hESC-CMs and hiPSC-CMs.
• To assess the efficacy of hPSC-CMs combined with impedance-based bioanalysis for cardiotoxicity screening.

Main Methods:

• Screening of four representative cardiotoxic drugs (E-4031, isoprenaline, quinidine, haloperidol).
• Utilizing both hESC-CMs and hiPSC-CMs for drug toxicity assessment.
• Employing an impedance-based bioanalytical method for high-throughput screening.

Main Results:

• Both hESC-CMs and hiPSC-CMs successfully replicated known cardiotoxic effects.
• The cell models accurately identified the impact of well-characterized cardiotoxic compounds.
• The study confirmed the utility of hPSC-CMs in modeling drug-induced cardiotoxicity.

Conclusions:

• The combined platform of hPSC-CMs and impedance-based bioanalysis significantly improves preclinical cardiotoxicity screening.
• This approach holds substantial potential for enhancing the accuracy and efficiency of drug development.
• Utilizing hPSC-CMs can lead to more reliable identification of potential cardiotoxic drugs early in the development pipeline.